🎉 Introducing our new website 🎉 ➡️ tvm-capital.com! More than just a redesign; it's a new way to experience TVM Capital Life Science. Click through to learn more about our unique strategy and witness innovation at its finest. #VC #LifeScience

🌟 Meet TVM at #BIOEurope Spring in Barcelona! 🚀Hubert Birner will speak on "Revolutionizing Drug Development" in a panel on March 19, 13:30-14:00. Let’s shape the future of #biopharma! #BIOEuropeSpring2024 #LifeScience

🚀 Excited for the LSI Emerging Medtech Summit, Dana Point, CA, MAR 18-22. A key event for innovators & investors in #medtech. We drive progress with investments in late-stage medical technologies – transforming healthcare, one innovation at a time. See you there! #MedTech #VC

🌐 TVM Capital Life Science applies strategic foresight in its investment into two med-tech companies @myo and @Vektor medical. Dive into TVM’s strategy to transform healthcare. Full insights on @BioWorld MedTech. ➡️ Read More: xitter.cf/BioWorldMedTech/status… #HealthcareInnovation

BIO-Europe is about to start in Munich! Watch below for insights from Managing Partner, Dr. Hubert Birner of @tvmcapital about this important event. You can hear the full interview with his thoughtful commentary here: youtube.com/watch?v=D4O6i8CL… #bioeurope2023

#BIOEurope2023 will soon kick off in our hometown of Munich! Dr. Hubert Birner, Managing Partner and Stefan Fischer, Managing Partner (Finance) of @tvmcapital will participate in panels at the conference. See the full agenda here: informaconnect.com/bioeurope…

Congrats to @GoingPublic_de - celebrating 25 years of reporting on the #biotech industry! Dr. Sascha Berger, General Partner of @tvmcapital will be part of the panel discussion "Venture Capital and Financing Trends in Changing Times" at 2:30 pm (CEST). #VC

Dr. Luc Marengère, Managing Partner, and Dr. Sascha Berger, General Partner at @tvmcapital are participating in the LSI Europe ’23 Emerging Medtech Summit, which takes place September 18-22, in Barcelona! Read more: lifesciencemarketresearch.co…

We are excited to announce that TVM, together with Tillots Pharma AG, will invest up to USD28m in the newly formed U.S.-based biotech company, Mage Biologics Inc., to develop an innovative oral antibody therapy for #UlcerativeColitis. tvm-lifescience.com/tillotts…

The @tvmcapital Life Science team is again participating in the BIO International Convention, which takes place June 5-8, in Boston! We look forward to meeting you there! #BIO2023 #VC

As a long-time industry expert, @tvmcapital Managing Partner Dr. Hubert Birner was happy to be a guest speaker at today's press event for this year’s Biotech Report and will moderate the panel "Investing in Biotech - but how?" at the report's presentation on June 27 in Munich.

@tvmcapital General Partner Dr. Sascha Berger has been invited to join the 2023 Nikkei Forum “Incubating Innovation in the Life Science Ecosystem” and will be participating in the panel “More than Money: The Investor’s Vantage Point: Fostering a Robust Start-up Ecosystem”.

Dr. Luc Marengère, Managing Partner, and Dr. Sascha Berger, General Partner at TVM are participating in the LSI USA ’23 Emerging Medtech Summit, which takes place March 20-23, in Dana Point, California, USA! tvm-lifescience.com/tvm-capi…

Our heartfelt congratulations to our TVM team members Dr. Valentina Agostini and Catello Somma on their promotions to Senior Associates and to Philipp Lechner on his promotion to Senior Associate Finance! Thank you for your hard work and your trust. tvm-lifescience.com/tvm-capi…

We are excited that @tvmcapital together with the @FondsFTQ will continue their support of Esperas Pharma to conduct a PoC study with first oral Check 1 inhibitor ESP-001 to treat #HGSOC. tvm-lifescience.com/esperas-…

We are excited to announce that we will invest up to USD 25 in U.S.-based #biotechnology company LAmAb Biologics, Inc., to develop a novel antibody therapy to clinical proof-of-concept to treat #allergy patients with a unique mechanism of action. tvm-lifescience.com/tvm-capi…

We are excited to announce that we will invest up to USD 24 million in U.S.-based #biotechnology company Recurv Pharma, Inc. to develop to proof-of-concept a novel #taxane therapy to treat #SolidTumors.